Central sleep apnea full details for md exams 10 marks answer from fishman and murray only

Reading File

Finding Sources

Reading File

I now have comprehensive content from both Fishman's and Murray & Nadel's. Let me compile a thorough 10-mark MD exam answer.

Central Sleep Apnea (CSA) - MD Exam Answer

Sources: Fishman's Pulmonary Diseases and Disorders (5e) & Murray & Nadel's Textbook of Respiratory Medicine (7e)

Definition

A central apnea results from a transient abolition of central respiratory drive to the respiratory muscles, leading to cessation of airflow - most often due to a fall in arterial PaCO2 below the threshold required to stimulate breathing (the apnea threshold). By convention, apnea is defined as absence or reduction of airflow to less than 90% of baseline for at least 10 seconds, with no chest wall or abdominal movement (distinguishing it from obstructive apnea).

A CSA disorder is defined as recurrent central apneas and hypopneas during sleep with an AHI where the majority of events are central. Severity: AHI 5-15 = mild; 15-30 = moderate; >30 = severe. CSA is much less common than OSA, with prevalence in the general population estimated at <1%.

(Fishman's, p. 1757; Murray & Nadel's, p. 2791)

Pathophysiology - Core Mechanism

The Apnea Threshold

During wakefulness, an endogenous "wakefulness stimulus" to breathe exists. With sleep onset, this stimulus withdraws and the chemical (metabolic) drive predominates. Minute ventilation falls 10-15% and PaCO2 rises 2-6 Torr.

Central apneas occur when arterial PaCO2 falls below the apneic threshold - the CO2 level necessary to maintain rhythmic breathing. Key causes of hypocapnia triggering this:

Sleep-state changes (arousal-driven hyperventilation)
Hypoxia
Fluctuations in minute ventilation (e.g., in heart failure)

(Fishman's, p. 1757)

Ventilatory Control Instability - Loop Gain

Several features promote and sustain recurring central apneas:

High loop gain: If the ventilatory response to CO2 changes is larger than needed for eupnea, self-sustaining oscillations occur where PaCO2 is repeatedly driven to the apneic threshold. This produces periodic breathing.
Circulatory delay: A lag between changes in ventilation and detection by central/peripheral chemoreceptors (as occurs when circulation time increases in heart failure) promotes oscillations.
Recurrent arousals: State changes from sleep to wakefulness re-engage the neurogenic drive, provoking ventilatory overshoot as PaCO2 is driven to the lower wakefulness set point. This is especially problematic in sleep-wake instability.

(Fishman's, p. 1758)

Classification

Murray & Nadel classifies CSA into two fundamental types based on waking PaCO2:

Feature	Hypercapnic CSA (PaCO2 > 45 mmHg)	Nonhypercapnic CSA (PaCO2 ≤ 45 mmHg)
Mechanism	Decreased respiratory drive or limited mechanical response	Normal or increased respiratory drive
Sex	Equal	Predominantly male
Respiratory failure history	Frequent	Not reported
Cor pulmonale	Frequent	Not reported
Morning headaches	Common	Uncommon
Nocturnal awakenings	Uncommon	Common
Hypertension	Uncommon	Common

(Murray & Nadel's, p. 2792, Table 121.2)

Hypercapnic CSA Subtypes

Secondary (most common):

Developmental/degenerative brainstem diseases
Brainstem tumors, cerebrovascular disease
Neuromuscular diseases (myasthenia gravis, bulbar poliomyelitis)
Shy-Drager syndrome, encephalitis

Primary:

Central alveolar hypoventilation syndrome (Ondine's curse)

The mechanism is outright defects in central respiratory drive or neuromuscular failure - the system cannot generate or transmit adequate motor output to respiratory muscles. Exacerbated during REM sleep when there is greatest reliance on diaphragm alone.

Nonhypercapnic CSA Subtypes

Secondary:

Cheyne-Stokes Respiration (CSR) in CHF (most common clinical form)
Cerebrovascular disease / stroke
Atrial fibrillation
Renal failure
Acromegaly
High altitude
Opioid use
Complex (treatment-emergent) sleep apnea

Primary:

Idiopathic CSA

Cheyne-Stokes Respiration (CSR-CSA) - Most Important Clinical Form

Epidemiology

CSR is most commonly seen in systolic heart failure. Risk factors in CHF patients include: male sex, age >65, atrial fibrillation, awake hypocapnia (PaCO2 <38 mmHg), diuretic use, lower LVEF, higher NYHA class, higher BNP, and higher pulmonary capillary wedge pressure. (Murray & Nadel's, p. 2799)

Pattern

CSR is characterized by prolonged hyperpneas with a waxing and waning (crescendo-decrescendo) respiratory pattern and prolonged cycle duration of 40-90 seconds (vs. shorter cycles of 12-34 s at high altitude). It is most prominent during NREM sleep when ventilation is under predominantly metabolic control.

Pathogenesis in Heart Failure

Increased central and peripheral chemoresponsiveness promotes hyperventilation and hypocapnia
Prolonged circulation time (from poor cardiac output) creates a longer delay between ventilatory changes and chemoreceptor detection, producing long-cycle periodic breathing
Arousals occur characteristically at the peak of hyperpnea (not at apnea termination, unlike OSA) - this provokes ventilatory overshoot sustaining the oscillations
Rostral fluid redistribution: Fluid accumulates in legs during the day and redistributes rostrally at night; in CSR, this fluid enters the lungs, stimulates pulmonary irritant receptors, causes hyperventilation and drives PaCO2 below the apnea threshold

(Fishman's, p. 1758; Murray & Nadel's, pp. 2799-2800)

Clinical Features of CSR-CSA

Symptoms include orthopnea, paroxysmal nocturnal dyspnea, witnessed apnea, fatigue, and insomnia. Notably, snoring and excessive daytime sleepiness are not characteristic features. (Murray & Nadel's, p. 2800)

Prognostic significance: CSR-CSA is a marker of worse prognosis in heart failure. The balance of evidence suggests it has an adverse impact on cardiac function and survival independently of other risk factors.

Diagnosis

Full overnight polysomnography (PSG) or home sleep apnea testing with instrumentation capable of detecting both respiratory effort and airflow limitation is required.

Respiratory inductance plethysmography is the gold standard for noninvasive detection of respiratory effort
Piezo-electric crystal bands, oronasal thermistors, and nasal pressure are not reliable for detecting presence/absence of respiratory effort
Key distinguishing feature: in CSA, chest wall and abdominal movement are absent during apnea, whereas in OSA, paradoxical chest-abdominal motion is seen
Differentiating central from obstructive hypopneas remains challenging, as both may show some respiratory effort

(Murray & Nadel's, p. 2791)

High-Altitude Periodic Breathing

At altitude, peripheral chemoreceptors (carotid body) sense hypoxia and increase ventilatory drive. As PaCO2 falls, the apnea threshold is crossed, precipitating central apneas and creating periodic breathing with short cycle times (12-34 s) due to brief circulation time. Gender differences exist: women have significantly fewer CSA events and longer respiratory cycles at altitude than men.

Treatment: Acetazolamide (alters the apnea threshold by raising the PCO2 required to produce central apneas); supplemental oxygen. (Fishman's, p. 1757)

Treatment

CSR-CSA in Heart Failure

1. Optimization of heart failure therapy - the first-line approach, as CSR-CSA may improve or resolve with improved cardiac function (beta-blockers, ACE inhibitors, cardiac resynchronization therapy).

2. Supplemental oxygen - reduces hypoxic drive to hyperventilation; improves overnight oxygenation and may reduce AHI.

3. Positive Airway Pressure:

CPAP: Reduces AHI and improves daytime sleepiness and quality of life; proposed mechanism is CO2 retention (raising PaCO2 above apnea threshold) and direct cardiac effects. The CANPAP trial showed CPAP suppressed CSA and improved some outcomes but did not improve transplant-free survival.
Adaptive Servo-Ventilation (ASV): Provides variable pressure support to counteract the ventilatory oscillations. Very effective at reducing AHI. However, the SERVE-HF trial showed that ASV was associated with increased cardiovascular mortality and all-cause mortality in patients with heart failure with reduced ejection fraction (HFrEF, LVEF ≤45%) with predominant CSA. ASV is therefore contraindicated in this population.
BiPAP/BPAP-ST: May be used in hypercapnic forms.

4. Acetazolamide - carbonic anhydrase inhibitor; creates metabolic acidosis stimulating ventilation and raising PaCO2 needed to reach apnea threshold. Reduces CSA and daytime sleepiness. Concerns: promotes transient sympathetic activation, potential hypokalemia, and cardiac arrhythmias; long-term safety unproven. Not routinely recommended.

5. Theophylline - adenosine antagonist that stimulates central respiratory drive and augments cardiac contractility; reduces AHI but no LVEF benefit and increases risk of cardiac arrhythmias and sudden death - not recommended.

6. CO2 inhalation / dead space addition - instantly abolishes CSR-CSA by raising PaCO2 above apnea threshold; no long-term benefit demonstrated, increases sympathetic activity.

7. Transvenous phrenic nerve stimulation - unilateral transvenous phrenic nerve pacing via superior vena cava; a multicenter RCT demonstrated 50%+ reduction in AHI in 93% of patients at 24 months (AHI from 47 to ~16/hour). Improvements in sleep architecture and quality of life sustained at 36 months and 5 years. Acceptable safety profile. FDA approved. (Murray & Nadel's, p. 2804; Fishman's, p. 1759)

Idiopathic CSA (ICSA)

A form without identifiable cardiac or neurologic cause. Rare (prevalence 0.4% in men, ~0% in women). Patients hyperventilate with low waking PaCO2 due to increased chemoreceptor responsiveness (high loop gain). Central apneas occur predominantly in NREM sleep; reduced in REM. Cycle time is shorter than CSR-CSA due to shorter circulation time.

Clinical: Middle-aged/older men; overweight; snoring, insomnia, restless sleep; may or may not have EDS.

Treatment (evidence limited):

CPAP (effective in some)
Acetazolamide (inconsistent results)
Sedatives/hypnotics (zolpidem, triazolam) to reduce arousal frequency and sleep instability - zolpidem reduced AHI by 55% in one open-label trial

(Murray & Nadel's, p. 2807; Fishman's, p. 1759)

Treatment-Emergent (Complex) CSA

Emergence of central apneas during CPAP titration for OSA. Prevalence: 5-15% of patients undergoing CPAP titration. More common in older males with low BMI and cardiac disease.

PSG shows central apneas in lighter sleep stages (N1, N2), with stable breathing in N3 and REM
Clinical relevance debated: only 20-25% of complex sleep apnea patients have persistent central apneas (>5/hr) after 1-3 months of CPAP
Causes: over/undertitration, occult heart failure, opioid/benzodiazepine use
Management: Trial of continued CPAP first (most resolve spontaneously); reserve ASV for persistent cases, including those on opioids

(Fishman's, p. 1759)

Key Points Summary (Murray & Nadel's)

CSA = cessation/reduction of airflow with absent or reduced respiratory effort, caused by PaCO2 falling below the apnea threshold
Two major types: hypercapnic (impaired drive/neuromuscular) and nonhypercapnic (augmented drive with instability)
CSR-CSA in heart failure is the most clinically significant form; ASV is contraindicated in HFrEF (LVEF ≤45%)
Phrenic nerve stimulation is an emerging effective therapy for CSR-CSA
ICSA is rare; treatment options are limited and evidence base is weak

Sources: Fishman's Pulmonary Diseases and Disorders, 2-Volume Set (5e), Chapter 98 (pp. 1757-1759); Murray & Nadel's Textbook of Respiratory Medicine, 2-Volume (7e), Chapter 121 (pp. 2791-2808)

This is a shared conversation. Sign in to Orris to start your own chat.